Tvardi Therapeutics, Inc.
TVRDTvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.
- Revenue
- +20.3%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.
Follow TVRD
Alert me
Tvardi Therapeutics, Inc. (TVRD) EV/Sales
As of Nov 20, 2026, Tvardi Therapeutics, Inc. (TVRD) trades at a EV/Sales of −1.3×. Over the past ten years it has ranged from −3.5× (February 2024) to 5,735× (March 2017); the current reading is higher than 7% of that period. That is below the Biotechnology industry median of 8.0× and below the Healthcare sector median of 3.1×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 6.4× | — |
| FY2023 | −2.9× | — |
| FY2022 | 10.5× | 215.08% |
| FY2021 | 3.3× | (16.22%) |
| FY2020 | 4.0× | (85.16%) |
| FY2019 | 26.9× | 27.10% |
| FY2018 | 21.2× | (93.14%) |
| FY2017 | 309× | (87.18%) |
| FY2016 | 2,409× | 2,873.16% |
| FY2015 | 81.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 0.7× | (89.83%) |
| Dec 2024 | 6.4× | — |
| Sep 2024 | −1.7× | — |
| Jun 2024 | −2.9× | — |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QNTM Quantum Biopharma Ltd. compare | −9.5× |
| TVRD Tvardi Therapeutics, Inc. | −1.3× |
| NEUP Neuphoria Therapeutics Inc. compare | −0.4× |
| CASIF CASI Pharmaceuticals Inc. compare | 0.9× |
| BOLT Bolt Biotherapeutics, Inc. compare | 2.6× |
| DYAI Dyadic International Inc. compare | 3.3× |
| GUTS Fractyl Health, Inc. compare | 93.7× |
| JSPR Jasper Therapeutics, Inc. compare | — |
| ACTU Actuate Therapeutics, Inc. compare | — |
| Biotechnology industry median | 8.0× |
| Healthcare sector median | 3.1× |
| Market median | 1.9× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)